Table 2.

Correlation of elevated β₂‐AR expression with clinicopathological parameters of prostate cancer

			β2‐AR
		Total	Expression low	Expression high	P value
Age, median (range)a, y	Tumor	n = 46	66 (51‐82) n = 14	70 (20‐87) n = 32	NS
Histology	Tumor	n = 46	n = 14	n = 32	<.001
	Normal	n = 15	n = 13	n = 2
	Hyperplasia	n = 6	n = 3	n = 3	NS
	Normal	n = 15	n = 13	n = 2
Clinical stage	cT1/2	n = 27	n = 7	n = 20	NS
	cT3/4	n = 19	n = 7	n = 12
Tumor grade	Gleason ≤6	n = 8	n = 0	n = 8	NS
	Gleason 7 (3 + 4)	n = 7	n = 2	n = 5
	Gleason 7 (4 + 3)	n = 2	n = 0	n = 2
	Gleason >7	n = 29	n = 12	n = 17
Pathologic stage	pT1‐pT2	n = 20	n = 3	n = 17	.050
	pT3	n = 24	n = 11	n = 13
Nodal status	pN0	n = 42	n = 12	n = 30	NS
	pN1	n = 4	n = 2	n = 2

Note: Tumor grade is presented as Gleason score. Comparison of unordered qualitative variables was performed using the χ ² test or Fisher's exact test depending on the conditions of validity (small numbers).

Abbreviation: β₂‐AR, β₂‐adrenergic receptor.

^aComparison of quantitative variable between patients with prostate cancer was performed using the student t test.